- Home
- GILD vs APP Comparison
GILD vs APP Comparison
Compare GILD & APP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | APP |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.6B | 166.9B |
| IPO Year | 2003 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GILD | APP |
|---|---|---|
| Price | $125.05 | $466.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 18 |
| Target Price | $148.39 | ★ $694.44 |
| AVG Volume (30 Days) | ★ 7.7M | 5.4M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | ★ 1684.21 | 115.23 |
| EPS | 1.61 | ★ 3.56 |
| Revenue | ★ $24,689,000,000.00 | $5,480,717,000.00 |
| Revenue This Year | $4.68 | $47.88 |
| Revenue Next Year | $6.04 | $29.14 |
| P/E Ratio | ★ $77.56 | $132.02 |
| Revenue Growth | 9.98 | ★ 16.38 |
| 52 Week Low | $107.75 | $325.69 |
| 52 Week High | $157.29 | $745.61 |
Technical Indicators
Market Signals| Indicator | GILD | APP |
|---|---|---|
| Relative Strength Index (RSI) | 42.66 | 40.92 |
| Support Level | $116.55 | $362.60 |
| Resistance Level | $126.46 | $499.42 |
| Average True Range (ATR) | 3.48 | 31.30 |
| MACD | -0.05 | -11.49 |
| Stochastic Oscillator | 36.81 | 13.18 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About APP Applovin Corporation
AppLovin is a vertically integrated advertising technology company that acts as a demand-side platform for advertisers, a supply-side platform for publishers, and an exchange facilitating transactions between the two. About 80% of AppLovin's revenue comes from the DSP, AppDiscovery, while the remainder comes from the SSP, Max. AppLovin's primary tool for future growth is AXON 2, which is an ad optimizer operating within the DSP that allows advertisers to place ads according to specified return thresholds.